血清基质金属蛋白酶-2在急性脑梗死患者TOAST各分型中含量的动态变化及意义
摘要
目的探讨血清基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)在急性脑梗死(acute cerebral infarction,ACI)患者TOAST(Trail of org 10172 inAcute Stroke Treatment)各病因分型中含量的动态变化及意义。
方法77例ACI患者按照TOAST标准进行病因分型,用ELISA(enzyme linkedimmunosorbent assay)法检测各分型脑梗死患者在发病第24小时,7天的血清MMP-2含量,及与之相匹配的42例正常对照者的血清MMP-2含量。从而比较MMP-2在急性脑梗死患者TOAST各病因分型中的含量动态变化。
结果TOAST病因分型构成LAA 37.66%,SAA 29.87%,CE 16.88%,SOE 6.49%,SUE9.09%。急性脑梗死组患者发病24小时,7天血清MMP-2水平均高于对照组(P＜0.05);TOAST各分型中,SOE、SUE因例数少未作分析,其它各型中,LAA、SAA、CE组血清MMP-2水平高于对照组(P＜0.05),其中以LAA组增高显著(P＜0.01)。经Logistic回归分析发现MMP-2、胆固醇及收缩压与脑血管病的发生呈正相关。
结论急性脑梗死患者血清MMP-2水平增高;MMP-2水平随TOAST亚型的不同而变化,在LAA中浓度升高最显著,支持脑梗死不同亚型可能具有不同病因的论点;血清MMP-2在LAA型脑梗死发病过程中起重要作用。
Objective To study the serial measurement and significance of matrix metaloproteinase-2 in serum of acute cerebral infarction patients according to TOAST criteria.
Methods 77 patients with acute cerebral infarction and 42 healthy individuals were enrolled in this trial.All the patients were classified into five subtypes according to TOAST criteria.Serum MMP-2 level was measured in patients according to TOAST criteria at hour 24 and day 7,and healthy people by ELISA.And then the relationship between MMP-2 level and their TOAST subtypes were analysed.
Results Of all the patients,37.66%,29.87%,16.88%,6.49%,9.09%were classified as 1 arge-artery atherosclerosis(LAA),small-artery occlusion lacunar(SAA), cardioembolism(CE),stroke of other demonstrated etiology(SOE),stroke of underdemonstrated etiology(SUE).Serum MMP-2 level of patients were significant higher than those of controls(p＜0.05);The level of the serum MMP-2 was much higher in patients with LAA SAA and CE than that in controls.As compared with the control group,The level of the serum MMP-2 in patients with LAA was the highest in ACI(P＜0.01).serum MMP-2 level of LAA at day 7 were significant higher than those of other subtypes and the control group.
Conclusions The serum MMP-2 level varied with different subtypes of ACI,specially elevating in subtypes LAA,which surported that the subtypes varied according to different pathogenies.
方法77例ACI患者按照TOAST标准进行病因分型,用ELISA(enzyme linkedimmunosorbent assay)法检测各分型脑梗死患者在发病第24小时,7天的血清MMP-2含量,及与之相匹配的42例正常对照者的血清MMP-2含量。从而比较MMP-2在急性脑梗死患者TOAST各病因分型中的含量动态变化。
结果TOAST病因分型构成LAA 37.66%,SAA 29.87%,CE 16.88%,SOE 6.49%,SUE9.09%。急性脑梗死组患者发病24小时,7天血清MMP-2水平均高于对照组(P＜0.05);TOAST各分型中,SOE、SUE因例数少未作分析,其它各型中,LAA、SAA、CE组血清MMP-2水平高于对照组(P＜0.05),其中以LAA组增高显著(P＜0.01)。经Logistic回归分析发现MMP-2、胆固醇及收缩压与脑血管病的发生呈正相关。
结论急性脑梗死患者血清MMP-2水平增高;MMP-2水平随TOAST亚型的不同而变化,在LAA中浓度升高最显著,支持脑梗死不同亚型可能具有不同病因的论点;血清MMP-2在LAA型脑梗死发病过程中起重要作用。
Objective To study the serial measurement and significance of matrix metaloproteinase-2 in serum of acute cerebral infarction patients according to TOAST criteria.
Methods 77 patients with acute cerebral infarction and 42 healthy individuals were enrolled in this trial.All the patients were classified into five subtypes according to TOAST criteria.Serum MMP-2 level was measured in patients according to TOAST criteria at hour 24 and day 7,and healthy people by ELISA.And then the relationship between MMP-2 level and their TOAST subtypes were analysed.
Results Of all the patients,37.66%,29.87%,16.88%,6.49%,9.09%were classified as 1 arge-artery atherosclerosis(LAA),small-artery occlusion lacunar(SAA), cardioembolism(CE),stroke of other demonstrated etiology(SOE),stroke of underdemonstrated etiology(SUE).Serum MMP-2 level of patients were significant higher than those of controls(p＜0.05);The level of the serum MMP-2 was much higher in patients with LAA SAA and CE than that in controls.As compared with the control group,The level of the serum MMP-2 in patients with LAA was the highest in ACI(P＜0.01).serum MMP-2 level of LAA at day 7 were significant higher than those of other subtypes and the control group.
Conclusions The serum MMP-2 level varied with different subtypes of ACI,specially elevating in subtypes LAA,which surported that the subtypes varied according to different pathogenies.
引文
Neumann-ttaefelin T,Kastrup A,Crespingny cerebral ischemia in rats,dynamics of tissue injury,blood brain barrier damage,and edema formation[J].Stroke,2000,31:1968-1973.
2 Rosenberg GA,Estrada BS,Dencoff JE.Matrix metalloproteinases and TIMPs are associated with blood brain barrier opening after reperfusion in rat brain[J].Stroke,1998,29:2189-2195.
3 落湘杭,廖二元,周后德,等.雌二醇对人成骨样细胞基质金属蛋白酶及其抑制因子的作用[J].中华内科杂志,2000,39:243-246.
4 王新德,各类脑血管病疾病诊断要点,中华神经科杂志,1996,29:379-381.
5 叶应妩,王毓三,申子瑜,等.全国临床检验操作规程[J].3版,南京:东南大学出版社,2006:423.
6 Wolfe CDA,Giroud M,Kolominsky-Rabas PL,et al.Variations in the incidence and survival of stroke in 3 areas of Europe.Stroke.2000,31:2074-2079.
7 Vemmos KN,Bots ML,Tsibouris PK,et al.Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry.Stroke.1999,30:363-370.
8 Kolominsky-Rabas PL,Sarti C,Heuschmann PU,Get al.A prospective community-based study of stroke in Germany:the Erlangen Stroke Project.Stroke.1998,29:2501- 2506.
9 Carolei A,Marini C,Di Napoli M,Oi Gianfilippo G,Santalucia P,Baldassarre M,De Matteis G,di Orio F.High stroke incidence in the prospective community-based L' Aquila registry(1994-1998):first year' s results.Stroke.1997,28:2500-2506.
10 Brown RD,Whisnant JP,Sicks JD,O' Fallon WM,Wiebers DO.Stroke incidence,prevalence,and survival:secular trends in Rochester,Minnesota,through 1989.Stroke.1996;27:373-380.
11 Feigin VL,Wiebers DO,Whisnant JP,et al.Stroke incidence and 30-day case-fatality rates in Novosibirsk,Russia,1982 through 1992.Stroke.1995,26:924-929.
12 Sarti C,Tuomilehto J,Sivenius J,et al.Declining trends in incidence,case-fatality and mortality of stroke in three geographic areas of Finland during 1983-1989:results from the FINMONICA stroke register.J Clin Epidemiol.1994,47:1259-1269.
13 Bonita R,Anderson CS,Broad JB,Jamrozik KD,Stewart-Wynne EG,Anderson NE.Stroke incidence and case fatality in Australasia:a comparison of the Auckland and Perth population-based stroke registers.Stroke.1994;25:552-557.
14 Czlonkowska A,Ryglewicz D,Weissbein T,et al.A prospective community-based study of stroke in Warsaw,Poland.Stroke.1994,25:547-551.
15 Jorgensen H,Plesner A,H(?)bbe P,et al.Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg,Denmark.Stroke.1992,23:1701-1704.
16 Ricci S,Celani MG,La Rosa F,et al.SEPIVAC:a community-based study of stroke incidence in Umbria,Italy.J Neurol Neurosurg Psychiatry.1991;54:695-698.
17 Giroud M,Beuriat P,Vion P,et al.Stroke in a French prospective population study.Neuroepidemiology,1989,8:97-104.
18 Bamford J,Sandercock P,Dennis M,et al.A prospective study of acute cerebrovascular disease in the community:the Oxfordshire Community Stroke Project 1981-86,1:methodology,demography and incident cases of first-ever stroke.J Neurol Neurosurg Psychiatry,1988,51:1373-1380.
19 Bamford J,Sandercock P,Dennis M.Classification and natural history of clinically identifiable subtypes of cerebral infarction.Lancet,1991,337:1521-1526.
20 Foulkes MA,Wolf PA,Price TR,et al.The Stroke Data Bank:design,methods,and baseline characteristics.Stroke,1988,19:547-554.
21 Malmgren R,Warlow C,Bamford J,et al.Geographical and secular trends in stroke incidence.Lancet,1987,2:1196-2000.
22 Bonita R.Epidemiology of stroke.Lancet.1992,339:342-344.
23 Sudlow CLM,Warlow CP.Comparing stroke incidence world-wide:what makes studies comparable? Stroke,1996,27:550-558.
24 Warlow CP.Epidemiology of stroke.Lancet.1998,352(suppl Ⅲ):1-4.
25 Adams HP,Bendixen BH,Kappelle LJ,et al.Classification of subtype of acute ischemic stroke[J].Stroke,1993,24(1):35-41.
26 Lee LJ,Kidwell CS,Alger J,et al.Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography.Stroke,2000,31:1081-1089.
27 Go rdon DL,Bendixen BH,Adams HP,et al.Interphysician agreement in the diagnosis of subtypes of acute ischem ic stroke[J].N euro logy,1993,43(5):1021-27.
28 Go ldstein LB,Jones MR,M atchar DB,et al.Improving the reliability of stroke subgroup classification using the trial of ORG 10172 in acute stroke treatment criteria[J].Stroke,2001,32(5):1091-97.
29 Kolom insky-Rabas PL Weber M,Gefeller O,et al.Epidemiology of ischemic stroke subtypes according to TOA ST criteria[J].Stroke,2001,32(12):2735-40.
30 Lee BI,Nam HS,Heo JH,et al.Yonsei stroke registry:analysis of 1000 patients with acute cerebral infartion[J].Cerebrovasc Dis,2001,12(3):145-151.
31 Yip PK,Jeng JS,Lee TK,et al.Subtypes of ischemic stroke:a hospital-based stroke registry in Taiwan(SCAN-Ⅳ)[J].Stroke,1997,28(12):2507-12.
32 Woo D,Gebel J,M iller R,et al.Incidence rates of first-ever ischemic stroke subtypes among blacks[J].Stroke,1999,30(12):2517-22.
33 Sapo snik G,Cap lan LR,onzalez LA,et al.Differences in stroke subtypes among natives and caucasians in boston and buenos aires[J].Stroke,2000,31(10):2385-89.
34 Newby AC.Dual Role of Matrix Metalloproteinases(Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture[J].Physiol Rev,2005,85(1):1-31.
35 Wang L,Zhang ZG,Zhang RL,et al.Matrix metalloproteinase- 2(MMP-2) and MMP-9secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration[J].J Neurosci,2006,26:5996.
36 CopinJC,Goodyear MC,Gidday JM,et al.Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice[J].Eur J Neurosci,2005,22:1597.
37 AoyagiM,et al.Histochem cell Biol,1998,109(2):97.
38 MAEDA A,SOBEL RA.Matrix metalloproteinases in the nomarl human central nervous system,microglial nodules,and multiple selerosis and stroke[J].J Neuropathol Exp Neurol,1996,55(3):300-309.
39 Romanic AM,White RF,Arleth AJ,et al.Matrix metalloproteinase expression increases after cerebral focal ischemia in rats.Stroke,1998,29(8):1020-1030.
40 KUGLER A.Matrixmetalloproteinasesandtheirinhititors[J].Anticancer Res,1999,19(2c):1589-1592.
41 Maclsaac AI,Thomas JD,Topoi EJ.Toward the quiescent coronary plaque[J].J Am Coll Cardiol,1993,22:1228-1241.
42 Steen DK,Ravn HB,Falk E.Insight into the pathophysiology of unstable coronary artery disease[J].Am J Cardiol,1997,80(5A):5-9.
43 吴平生,张远慧,许乙凯,等.易损斑块及易损患者的新定义及危险分层[J].中华心血管病杂志,2004,32(3):283-285.
44 张涛,李自成.冠心病易损斑块的研究进展[J].临床心血管病杂志,2004,20(8):509-512.
45 Moreno PR,Lodder RA,Purushothaman KR,et al.Detection of lipid pool,thin fibrous cap,and inflammatory cells inhuman aortic atherosclerotic plaques by near2infarcted spectroscopy[J].Circulation,2002,105(8):923-927.
46 Bea F,Blessing E,Bennett B,et al.Simvastatin promotes atherosclerotic plaque stability in apoE2 deficient mice independently of lipid lowering[J].Arterioscler Thromb Vase Biol,2002,22(11):1 832-837.
47 Davies MJ,Richardson PD,Woolf N,et al.Risk of thrombosis in human atherosclerotic plaque:role of extracellular lipid,macrophage,and smooth muscle cell content[J].Br Heart J,1993,69:377-381.
48 Lessener SM,Gallis Zs.Matrix metalloproteinase and vascular endothelium-mononuclear cell close encounters[J].Trends Cardiovasc Msd,2004,14:105-111.
49 Pasterkamp G,Schoneveld AH,Hijnen DJ,et al.Atherosclerotic arterial remodeling and the localization of macrophages and matrix metallo-proteinasel,2 and 9 in the human coronary artery.Atherosclerosis,2000,150:245-253.
50 Brown DL,Hibbs MS,Kearney M,et al.Identification of 922kD gelatinase in human coronary atherosclerotic lesions.Association of active enzyme synthesis with unstable angina[J].Circulation,1995,91(8):2125-2131.
51 Shah PK,Falk E Badimon JJ,et al.Human monocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques.Potential role of matrix degrading metalloproteinases and implications for plaque rupture[J].Circulation,1995,92(6):1565-1569.
52 朱伟旺,赵凤琴.基质金属蛋白酶与急性冠脉综合症[J].吉林医学,2007,8(28):1143-1145.
53 Aoyagi M,et al.Histochem cell Biol,1998,109(2):97.
54 Chen J,Han Y,Lin C,et al.PDGF-D contributes toneointimal hyperplasia in rat model of vessel injuiy[J].Biochem Biophys Res Commun,2005,329:976.
55 Kanda s,Kuzuya M,Ram os MA,et al.Matrix metalloproteinase and α β 3integrin-dependent vascular smooth muscle cell invasion through a type Ⅰ collagen lattice[J].Arterioscler Thromb Vasc Biol,2000,20:99.
56 Newby AC.Dual Role of matrix metalloproteinses(Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture.Physiol Rev,2005,85(1):1-31.
57 Horstmann S,Kalb P,Koziol J,et al.Profiles of matrix metalloproteinases,their inhibitors,and laminin in stroke patients:influence of different therapies.Stroke,2003,34(9):2165-2170.
58 Yang GY,et al.Stroke,1994,25:1658.
59 Rosenberg GA,et al.Neurology,1996,46(6):1626.
60 Adams H,Davis P.Baseline NIH Stroke Scale score strongly predicts outcome after stroke:A report of t he Trial of Org10172 in Acute Stroke Treatment(TOAST)[J].Neurology,1999,53(1):126-131.
1.Nagasa H,WoessnerJF JR.Matrix metalloprotienases.J Biol Chem,1999,274:21491-94.
2.Kuzuya M,Lguchi A.Role of matrix metalloproteinases in vascular remodeling.J Atheroscler Thromb,2003,10:275-282.
3.Murphy G,et al.Biochem J.1989;258:463-472.
4.Somerville RP,Oblander SA,Apte SS.Matrix metalloproteinases old dogs with new tricks.2003,4:216.
5.Rodriguez-Pla A,Bosch-Gil JA,Rossello-Urgell J,et al.Metalloprotei--nase-2 and-9 in giant cell arteritis:involvement in vascular remodeling.Circulation,2005,112:264-269.
6.Vanwart HE.Pro Nat Acad Sci USA,1990,87:5578-5582.
7.KUGLER A.Matrix metalloproteinases and their inhititors[J].Anticancer Res,1999,19(2c):1589-1592.
8.Jacob MP.Extracellular matrix remodeling and matrix metalloprotein--ases in the vascular wall during aging and in pathological conditions.Biomed Pharmacother,2003,57:195-202.
9.Bouvet C,Gilbert LA,Girardot D,et al.Different involve--ment of extracellular matrix components in small and large arteries during chronic NO synthase inhibition.Hypertension,2005,45:432-437.
10.Galis ZS,Khatri JJ.Matrix metalloproteinases in vascular remodeling and atherogenesis:the good,the bad,and the ugly.Circ Res,2002,90:251-262.
11.Bendeck MP,Conte M,Zhang M,et al.Doxycycline modulates smooth muscle cell growth,migration,and matrix remodeling after arterial injury.Am J Pathol,2002,160:1089-1095.
12.Prescott MF,Sawyer WK,Von Linden-Reed J,et al.Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice over-expressing MMP-3,MMP-12,and MMP-13 and on restenosis in rats after balloon injury.Ann NY Acad Sci,1999,878:179-190.
13.Dollery CM,Humphries SE,McClelland A,et al.Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury.Circulation,1999,99:3199-3205.
14.Kuzuya M,Kanda S,Sasaki T,et al.Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia.Circulation,2003,108:1375-1381.
15.Johnson C,Galis ZS.Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization.Arteioscler Thromb Vase Biol,2004,4:54 -60.
16.Libby P.Changing concepts of atherogenesis[J].J Intem Med.,2000,247:349-358.
17.谢逸群,杨期东.MMP-2、MMP-9与脑缺血损伤研究进展[J].国外医学:神经病学神经外科分册,2000,27:172-174.
18.Pasterkamp G,Schoneveld AH,Hijnen DJ,et al.Atherosclerotic arterial remodeling and the localization of macrophages and matrix metallo- proteinase 1,2and 9 in the human coronary artery.Atherosclerosis,2000,150:245-253.
19.Cuzner ML,Cveric D,Strand C,et al.The expression of tissue-type plasminogen activator,matrix metalloproteinases and endoge-nousinhibitoris in the central nervous system in multiple sclerosis:comparison of stages in lesion evolution[J].J Neuropathol Exp Neurol,1996,55(12):1194-1204.
20.Raeda A,Sobel RA.Matrix metalloproteinases in the nomarl human central nervous system,microglial nodules,and multiple sclerosis and stroke[J].J Neuropathol Exp Neurol,1996,55(3):300-309.
21.Newby AC,Dual Role of matrix metalloproteinses(Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture.Physiol Rev,2005,85(1):1-31.
22.Ding YH,Li J,Rafols JA,et al.Reduced brain edema and matrix metalloproteinase(MMP)expression by pre-reperfusion infusion into ischemic territory in rat Neuosci Lett,2004,372(12):35-39.
23.Montaner J,Alvarez-Sabin J,Molina C,et al.Matrix metalloproteinase expression after human cardioembolic stroke:temporal profile and relation to neurological impaiment Stroke,2001,32(8):1750-1766.
24.Jian Liu K,Rosenberg GA.Matrix metalloproteinases and free radicals in cerebral ischemia.Free Radic Biol Med,2005,39(1):71-80.
25.Horstmann S,Kalb P,Koziol J,et al.Profiles of matrix metalloproteinases,their inhibitors,and laminin in stroke patients:influence of different therapies.Stroke,2003,34(9):2165-2170.
26.Romantic AM,White RF,Arleth AJ,et al.Matrix metalloproteinase expression increases sfter cerebral focal ischemia in rats.Inhibition of matrix metalloproteinase-9 reduces infarct size.Stroke,1998,29(8):1020-1030.
27.Madri JA,et al.Biochem Cell Biol,1996;74(6):749.
28.Heo JH,Lucero J,Abumiya T,et al.Matrix metalloproteinases increase very early during ecperimental focal cerebral ischemia[J].J cereb Blood Flow Metab,1999,19(6):624-633.
29.Wolfe CDA,Giroud M,Kolominsky-Rabas PL,Dundas R,Lemesle M,Heuschmann PU,Rudd AG.Variations in the incidence and survival of stroke in 3 areas of Europe.Stroke,2000,31:2074-2079.
30.Vemmos KN,Bots ML,Tsibouris PK,Zis VP,Grobbee DE,Stranjalis GS,Stamatelopoulos S.Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry.Stroke,1999,30:363-370.
31.Kolominsky-Rabas PL,Sarti C,Heuschmann PU,Graf C,et al.A prospective community-based study of stroke in Germany:the Erlangen Stroke Project.Stroke,1998,29:2501-2506.
32.Carolei A,Marini C,Di Napoli M,et al.High stroke incidence in the prospective community-based L' Aquila registry(1994-1998):first year's results.Stroke,1997,28:2500-2506.
33.Brown RD,Whisnant JP,Sicks JD,et al.Stroke inci-dence,prevalence,and survival:secular trends in Rochester,Minnesota,through 1989.Stroke,1996,27:373-380.
34.Feigin VL,Wiebers DO,Whisnant JP,O'Fallon WM.Stroke incidence and 30-day case-fatality rates in Novosibirsk,Russia,1982 through 1992.Stroke.1995,26:924-929.
35.Sarti C,Tuomilehto J,Sivenius J,et al.Declining trends in incidence,case-fatality and mortality of stroke in three geographic areas of Finland during 1983-1989:results from the FINMONICA stroke register.J Clin Epidemiol,1994,47:1259-1269.
36.Bonita R,Anderson CS,Broad JB,et al.Stroke incidence and case fatality in Australasia:a comparison of the Auckland and Perth population-based stroke registers.Stroke,1994,25:552-557.
37.Czlonkowska A,Ryglewicz D,Weissbein T,et al.A prospective community-based study of stroke in Warsaw,Poland.Stroke,1994,25:547-551.
38.Jorgensen H,Plesner A,HUbbe P,et al.Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg,Denmark.Stroke,1992,23:1701-1704.
39.Ricci S,Celani MG,La Rosa F,et al.SEPIVAC:a community-based study of stroke incidence in Umbria,Italy.J Neurol Neurosurg Psychiatry,1991,54:695-698.
40.Giroud M,Beuriat P,Vion P,et al.Stroke in a French prospective population study.Neuroepidemiology,1989,8:97-104.
41.Bamford J,Sandercock P,Dennis M,et al.A prospective study of acute cerebrovascular disease in the community:the Oxfordshire Community Stroke Project 1981-86,1:methodology,demography and incident cases of first-ever stroke.J Neurol Neurosurg Psychiatry,1988,51:1373-1380.
42.Bamford J,Sandercock P,Dennis M.Classification and natural history of clinically identifiable subtypes of cerebral infarction.Lancet,1991,337:1521-1526.
43.Foulkes MA,Wolf PA,Price TR,et al.The Stroke Data Bank:design,methods,and baseline characteristics.Stroke,1988,19:547-554.
44.Malmgren R,Warlow C,Bamford J,et al.Geographical and secular trends in stroke incidence.Lancet,1987,2:1196-2000.
45.Bonita R.Epidemiology of stroke.Lancet,1992,339:342-344.
46.Sudlow CLM,Warlow CP.Comparing stroke incidence world-wide:what makes studies comparable?Stroke,1996,27:550-558.
47.Warlow CP.Epidemiology of stroke.Lancet.1998,352(suppl Ⅲ):1-4.
48.Adams HP,Bendixen BH,Kappelle LJ,et al.Classification of subtype of acute ischemic stroke[J].Stroke,1993,24(1):35-41.
49.Albanese MA,Clarke WR,Adams HP,et al.Stroke,1994,25:1746-49.
50.Madden KP,Madden M,Adama HP,et al.Neurology.1995,45:1975-61.
51.Lee LJ,Kidwell CS,Alger J,et al.Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography.Stroke,2000,31:1081-1089.
52.Johnson BA,Haiserman JE.Am J Neuroradiol.1994,15:901-906.
53.Gordon DL,Bendixen BH,Adams HP,et al.Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke[J].Neurology,1993,43(5):1021-27.
54.Goldstein LB,Jones MR,Matchar DB,et al.Improving the reliability of stroke subgroup classification using the trial of 0RG10172 in acute stroke treatment criteria[J].Stroke,2001,32(5):1091-97.
55.Kolom insky-Rabas PL,Weber M,Gefeller O,et al.Epidemiology of ischem-ic stroke subtypes according to TOAST criteria[J].Stroke.2001,32(12):2735-40.
56.Lee BI,Nam HS,Heo JH,et al.Yonsei stroke registry:analysis of 1000 patients with acute cerebral infartion[J].Cerebrovasc Dis,2001,12(3):145-151.
57.Yip PK,Jeng JS,Lee TK,et al.Subtypes of ischem ic stroke:a hospital-based stroke registry in Taiwan(SCAN-IV)[J].Stroke,1997,28(12):2507-2512.
58.Adams H,Davis P.Baseline NIH Stroke Scale score strongly predicts outcome after stroke:A report of t he Trial of Org10172 in Acute Stroke Treatment(TOAST)[J].Neurology,1999,53(1):126-131.
59.Kanda S,Kuzuya M,Ramos MA,et al.Matrix metalloproteinase and α β3 integrin-dependent vascular smooth muscle cee invasion through a type I collagen lattice[J].Arterioscler Thromb Vase Biol.2000,20:998.
60.Liu YN,Pan SL,Peng CY,et al.YC-1[3-(5-Hydroxymethyl-2-furyl)-1-benzyl Indazole]inhibits neointim a formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metallopreteinases 2 and 9[J].J Phamacol Ecp Ther,2006,316:35.
61.Lapchak PA,Chapman DF,Zivin JA.Metallopreteinase inhibition reduces thrombolytic(tissue plasminogen activator) induced hemorrhage after thromboembolic stroke[J].Stroke,2000,31(12):3034-3040.
62.Pfefferkom T,Rosenberg GA.Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion[J].Stroke,2003,34(8):2025-2030.
63.Wilson SH,Herrmann J,Lerman Lo,et al.Aimvastatin preserves the structure of coronary adwentitial vasoram in experimental hypercholesterolemia independent of lipid lowering[J].Circulation,2002,105:415-418.
64.Som JW,Koh KK,Ahm JY,et al.Effects of statin on plague stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease[J].Int J Cardiol,2003,88:77-82.
2 Rosenberg GA,Estrada BS,Dencoff JE.Matrix metalloproteinases and TIMPs are associated with blood brain barrier opening after reperfusion in rat brain[J].Stroke,1998,29:2189-2195.
3 落湘杭,廖二元,周后德,等.雌二醇对人成骨样细胞基质金属蛋白酶及其抑制因子的作用[J].中华内科杂志,2000,39:243-246.
4 王新德,各类脑血管病疾病诊断要点,中华神经科杂志,1996,29:379-381.
5 叶应妩,王毓三,申子瑜,等.全国临床检验操作规程[J].3版,南京:东南大学出版社,2006:423.
6 Wolfe CDA,Giroud M,Kolominsky-Rabas PL,et al.Variations in the incidence and survival of stroke in 3 areas of Europe.Stroke.2000,31:2074-2079.
7 Vemmos KN,Bots ML,Tsibouris PK,et al.Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry.Stroke.1999,30:363-370.
8 Kolominsky-Rabas PL,Sarti C,Heuschmann PU,Get al.A prospective community-based study of stroke in Germany:the Erlangen Stroke Project.Stroke.1998,29:2501- 2506.
9 Carolei A,Marini C,Di Napoli M,Oi Gianfilippo G,Santalucia P,Baldassarre M,De Matteis G,di Orio F.High stroke incidence in the prospective community-based L' Aquila registry(1994-1998):first year' s results.Stroke.1997,28:2500-2506.
10 Brown RD,Whisnant JP,Sicks JD,O' Fallon WM,Wiebers DO.Stroke incidence,prevalence,and survival:secular trends in Rochester,Minnesota,through 1989.Stroke.1996;27:373-380.
11 Feigin VL,Wiebers DO,Whisnant JP,et al.Stroke incidence and 30-day case-fatality rates in Novosibirsk,Russia,1982 through 1992.Stroke.1995,26:924-929.
12 Sarti C,Tuomilehto J,Sivenius J,et al.Declining trends in incidence,case-fatality and mortality of stroke in three geographic areas of Finland during 1983-1989:results from the FINMONICA stroke register.J Clin Epidemiol.1994,47:1259-1269.
13 Bonita R,Anderson CS,Broad JB,Jamrozik KD,Stewart-Wynne EG,Anderson NE.Stroke incidence and case fatality in Australasia:a comparison of the Auckland and Perth population-based stroke registers.Stroke.1994;25:552-557.
14 Czlonkowska A,Ryglewicz D,Weissbein T,et al.A prospective community-based study of stroke in Warsaw,Poland.Stroke.1994,25:547-551.
15 Jorgensen H,Plesner A,H(?)bbe P,et al.Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg,Denmark.Stroke.1992,23:1701-1704.
16 Ricci S,Celani MG,La Rosa F,et al.SEPIVAC:a community-based study of stroke incidence in Umbria,Italy.J Neurol Neurosurg Psychiatry.1991;54:695-698.
17 Giroud M,Beuriat P,Vion P,et al.Stroke in a French prospective population study.Neuroepidemiology,1989,8:97-104.
18 Bamford J,Sandercock P,Dennis M,et al.A prospective study of acute cerebrovascular disease in the community:the Oxfordshire Community Stroke Project 1981-86,1:methodology,demography and incident cases of first-ever stroke.J Neurol Neurosurg Psychiatry,1988,51:1373-1380.
19 Bamford J,Sandercock P,Dennis M.Classification and natural history of clinically identifiable subtypes of cerebral infarction.Lancet,1991,337:1521-1526.
20 Foulkes MA,Wolf PA,Price TR,et al.The Stroke Data Bank:design,methods,and baseline characteristics.Stroke,1988,19:547-554.
21 Malmgren R,Warlow C,Bamford J,et al.Geographical and secular trends in stroke incidence.Lancet,1987,2:1196-2000.
22 Bonita R.Epidemiology of stroke.Lancet.1992,339:342-344.
23 Sudlow CLM,Warlow CP.Comparing stroke incidence world-wide:what makes studies comparable? Stroke,1996,27:550-558.
24 Warlow CP.Epidemiology of stroke.Lancet.1998,352(suppl Ⅲ):1-4.
25 Adams HP,Bendixen BH,Kappelle LJ,et al.Classification of subtype of acute ischemic stroke[J].Stroke,1993,24(1):35-41.
26 Lee LJ,Kidwell CS,Alger J,et al.Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography.Stroke,2000,31:1081-1089.
27 Go rdon DL,Bendixen BH,Adams HP,et al.Interphysician agreement in the diagnosis of subtypes of acute ischem ic stroke[J].N euro logy,1993,43(5):1021-27.
28 Go ldstein LB,Jones MR,M atchar DB,et al.Improving the reliability of stroke subgroup classification using the trial of ORG 10172 in acute stroke treatment criteria[J].Stroke,2001,32(5):1091-97.
29 Kolom insky-Rabas PL Weber M,Gefeller O,et al.Epidemiology of ischemic stroke subtypes according to TOA ST criteria[J].Stroke,2001,32(12):2735-40.
30 Lee BI,Nam HS,Heo JH,et al.Yonsei stroke registry:analysis of 1000 patients with acute cerebral infartion[J].Cerebrovasc Dis,2001,12(3):145-151.
31 Yip PK,Jeng JS,Lee TK,et al.Subtypes of ischemic stroke:a hospital-based stroke registry in Taiwan(SCAN-Ⅳ)[J].Stroke,1997,28(12):2507-12.
32 Woo D,Gebel J,M iller R,et al.Incidence rates of first-ever ischemic stroke subtypes among blacks[J].Stroke,1999,30(12):2517-22.
33 Sapo snik G,Cap lan LR,onzalez LA,et al.Differences in stroke subtypes among natives and caucasians in boston and buenos aires[J].Stroke,2000,31(10):2385-89.
34 Newby AC.Dual Role of Matrix Metalloproteinases(Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture[J].Physiol Rev,2005,85(1):1-31.
35 Wang L,Zhang ZG,Zhang RL,et al.Matrix metalloproteinase- 2(MMP-2) and MMP-9secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration[J].J Neurosci,2006,26:5996.
36 CopinJC,Goodyear MC,Gidday JM,et al.Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice[J].Eur J Neurosci,2005,22:1597.
37 AoyagiM,et al.Histochem cell Biol,1998,109(2):97.
38 MAEDA A,SOBEL RA.Matrix metalloproteinases in the nomarl human central nervous system,microglial nodules,and multiple selerosis and stroke[J].J Neuropathol Exp Neurol,1996,55(3):300-309.
39 Romanic AM,White RF,Arleth AJ,et al.Matrix metalloproteinase expression increases after cerebral focal ischemia in rats.Stroke,1998,29(8):1020-1030.
40 KUGLER A.Matrixmetalloproteinasesandtheirinhititors[J].Anticancer Res,1999,19(2c):1589-1592.
41 Maclsaac AI,Thomas JD,Topoi EJ.Toward the quiescent coronary plaque[J].J Am Coll Cardiol,1993,22:1228-1241.
42 Steen DK,Ravn HB,Falk E.Insight into the pathophysiology of unstable coronary artery disease[J].Am J Cardiol,1997,80(5A):5-9.
43 吴平生,张远慧,许乙凯,等.易损斑块及易损患者的新定义及危险分层[J].中华心血管病杂志,2004,32(3):283-285.
44 张涛,李自成.冠心病易损斑块的研究进展[J].临床心血管病杂志,2004,20(8):509-512.
45 Moreno PR,Lodder RA,Purushothaman KR,et al.Detection of lipid pool,thin fibrous cap,and inflammatory cells inhuman aortic atherosclerotic plaques by near2infarcted spectroscopy[J].Circulation,2002,105(8):923-927.
46 Bea F,Blessing E,Bennett B,et al.Simvastatin promotes atherosclerotic plaque stability in apoE2 deficient mice independently of lipid lowering[J].Arterioscler Thromb Vase Biol,2002,22(11):1 832-837.
47 Davies MJ,Richardson PD,Woolf N,et al.Risk of thrombosis in human atherosclerotic plaque:role of extracellular lipid,macrophage,and smooth muscle cell content[J].Br Heart J,1993,69:377-381.
48 Lessener SM,Gallis Zs.Matrix metalloproteinase and vascular endothelium-mononuclear cell close encounters[J].Trends Cardiovasc Msd,2004,14:105-111.
49 Pasterkamp G,Schoneveld AH,Hijnen DJ,et al.Atherosclerotic arterial remodeling and the localization of macrophages and matrix metallo-proteinasel,2 and 9 in the human coronary artery.Atherosclerosis,2000,150:245-253.
50 Brown DL,Hibbs MS,Kearney M,et al.Identification of 922kD gelatinase in human coronary atherosclerotic lesions.Association of active enzyme synthesis with unstable angina[J].Circulation,1995,91(8):2125-2131.
51 Shah PK,Falk E Badimon JJ,et al.Human monocyte derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques.Potential role of matrix degrading metalloproteinases and implications for plaque rupture[J].Circulation,1995,92(6):1565-1569.
52 朱伟旺,赵凤琴.基质金属蛋白酶与急性冠脉综合症[J].吉林医学,2007,8(28):1143-1145.
53 Aoyagi M,et al.Histochem cell Biol,1998,109(2):97.
54 Chen J,Han Y,Lin C,et al.PDGF-D contributes toneointimal hyperplasia in rat model of vessel injuiy[J].Biochem Biophys Res Commun,2005,329:976.
55 Kanda s,Kuzuya M,Ram os MA,et al.Matrix metalloproteinase and α β 3integrin-dependent vascular smooth muscle cell invasion through a type Ⅰ collagen lattice[J].Arterioscler Thromb Vasc Biol,2000,20:99.
56 Newby AC.Dual Role of matrix metalloproteinses(Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture.Physiol Rev,2005,85(1):1-31.
57 Horstmann S,Kalb P,Koziol J,et al.Profiles of matrix metalloproteinases,their inhibitors,and laminin in stroke patients:influence of different therapies.Stroke,2003,34(9):2165-2170.
58 Yang GY,et al.Stroke,1994,25:1658.
59 Rosenberg GA,et al.Neurology,1996,46(6):1626.
60 Adams H,Davis P.Baseline NIH Stroke Scale score strongly predicts outcome after stroke:A report of t he Trial of Org10172 in Acute Stroke Treatment(TOAST)[J].Neurology,1999,53(1):126-131.
1.Nagasa H,WoessnerJF JR.Matrix metalloprotienases.J Biol Chem,1999,274:21491-94.
2.Kuzuya M,Lguchi A.Role of matrix metalloproteinases in vascular remodeling.J Atheroscler Thromb,2003,10:275-282.
3.Murphy G,et al.Biochem J.1989;258:463-472.
4.Somerville RP,Oblander SA,Apte SS.Matrix metalloproteinases old dogs with new tricks.2003,4:216.
5.Rodriguez-Pla A,Bosch-Gil JA,Rossello-Urgell J,et al.Metalloprotei--nase-2 and-9 in giant cell arteritis:involvement in vascular remodeling.Circulation,2005,112:264-269.
6.Vanwart HE.Pro Nat Acad Sci USA,1990,87:5578-5582.
7.KUGLER A.Matrix metalloproteinases and their inhititors[J].Anticancer Res,1999,19(2c):1589-1592.
8.Jacob MP.Extracellular matrix remodeling and matrix metalloprotein--ases in the vascular wall during aging and in pathological conditions.Biomed Pharmacother,2003,57:195-202.
9.Bouvet C,Gilbert LA,Girardot D,et al.Different involve--ment of extracellular matrix components in small and large arteries during chronic NO synthase inhibition.Hypertension,2005,45:432-437.
10.Galis ZS,Khatri JJ.Matrix metalloproteinases in vascular remodeling and atherogenesis:the good,the bad,and the ugly.Circ Res,2002,90:251-262.
11.Bendeck MP,Conte M,Zhang M,et al.Doxycycline modulates smooth muscle cell growth,migration,and matrix remodeling after arterial injury.Am J Pathol,2002,160:1089-1095.
12.Prescott MF,Sawyer WK,Von Linden-Reed J,et al.Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice over-expressing MMP-3,MMP-12,and MMP-13 and on restenosis in rats after balloon injury.Ann NY Acad Sci,1999,878:179-190.
13.Dollery CM,Humphries SE,McClelland A,et al.Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury.Circulation,1999,99:3199-3205.
14.Kuzuya M,Kanda S,Sasaki T,et al.Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia.Circulation,2003,108:1375-1381.
15.Johnson C,Galis ZS.Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization.Arteioscler Thromb Vase Biol,2004,4:54 -60.
16.Libby P.Changing concepts of atherogenesis[J].J Intem Med.,2000,247:349-358.
17.谢逸群,杨期东.MMP-2、MMP-9与脑缺血损伤研究进展[J].国外医学:神经病学神经外科分册,2000,27:172-174.
18.Pasterkamp G,Schoneveld AH,Hijnen DJ,et al.Atherosclerotic arterial remodeling and the localization of macrophages and matrix metallo- proteinase 1,2and 9 in the human coronary artery.Atherosclerosis,2000,150:245-253.
19.Cuzner ML,Cveric D,Strand C,et al.The expression of tissue-type plasminogen activator,matrix metalloproteinases and endoge-nousinhibitoris in the central nervous system in multiple sclerosis:comparison of stages in lesion evolution[J].J Neuropathol Exp Neurol,1996,55(12):1194-1204.
20.Raeda A,Sobel RA.Matrix metalloproteinases in the nomarl human central nervous system,microglial nodules,and multiple sclerosis and stroke[J].J Neuropathol Exp Neurol,1996,55(3):300-309.
21.Newby AC,Dual Role of matrix metalloproteinses(Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture.Physiol Rev,2005,85(1):1-31.
22.Ding YH,Li J,Rafols JA,et al.Reduced brain edema and matrix metalloproteinase(MMP)expression by pre-reperfusion infusion into ischemic territory in rat Neuosci Lett,2004,372(12):35-39.
23.Montaner J,Alvarez-Sabin J,Molina C,et al.Matrix metalloproteinase expression after human cardioembolic stroke:temporal profile and relation to neurological impaiment Stroke,2001,32(8):1750-1766.
24.Jian Liu K,Rosenberg GA.Matrix metalloproteinases and free radicals in cerebral ischemia.Free Radic Biol Med,2005,39(1):71-80.
25.Horstmann S,Kalb P,Koziol J,et al.Profiles of matrix metalloproteinases,their inhibitors,and laminin in stroke patients:influence of different therapies.Stroke,2003,34(9):2165-2170.
26.Romantic AM,White RF,Arleth AJ,et al.Matrix metalloproteinase expression increases sfter cerebral focal ischemia in rats.Inhibition of matrix metalloproteinase-9 reduces infarct size.Stroke,1998,29(8):1020-1030.
27.Madri JA,et al.Biochem Cell Biol,1996;74(6):749.
28.Heo JH,Lucero J,Abumiya T,et al.Matrix metalloproteinases increase very early during ecperimental focal cerebral ischemia[J].J cereb Blood Flow Metab,1999,19(6):624-633.
29.Wolfe CDA,Giroud M,Kolominsky-Rabas PL,Dundas R,Lemesle M,Heuschmann PU,Rudd AG.Variations in the incidence and survival of stroke in 3 areas of Europe.Stroke,2000,31:2074-2079.
30.Vemmos KN,Bots ML,Tsibouris PK,Zis VP,Grobbee DE,Stranjalis GS,Stamatelopoulos S.Stroke incidence and case fatality in southern Greece:the Arcadia stroke registry.Stroke,1999,30:363-370.
31.Kolominsky-Rabas PL,Sarti C,Heuschmann PU,Graf C,et al.A prospective community-based study of stroke in Germany:the Erlangen Stroke Project.Stroke,1998,29:2501-2506.
32.Carolei A,Marini C,Di Napoli M,et al.High stroke incidence in the prospective community-based L' Aquila registry(1994-1998):first year's results.Stroke,1997,28:2500-2506.
33.Brown RD,Whisnant JP,Sicks JD,et al.Stroke inci-dence,prevalence,and survival:secular trends in Rochester,Minnesota,through 1989.Stroke,1996,27:373-380.
34.Feigin VL,Wiebers DO,Whisnant JP,O'Fallon WM.Stroke incidence and 30-day case-fatality rates in Novosibirsk,Russia,1982 through 1992.Stroke.1995,26:924-929.
35.Sarti C,Tuomilehto J,Sivenius J,et al.Declining trends in incidence,case-fatality and mortality of stroke in three geographic areas of Finland during 1983-1989:results from the FINMONICA stroke register.J Clin Epidemiol,1994,47:1259-1269.
36.Bonita R,Anderson CS,Broad JB,et al.Stroke incidence and case fatality in Australasia:a comparison of the Auckland and Perth population-based stroke registers.Stroke,1994,25:552-557.
37.Czlonkowska A,Ryglewicz D,Weissbein T,et al.A prospective community-based study of stroke in Warsaw,Poland.Stroke,1994,25:547-551.
38.Jorgensen H,Plesner A,HUbbe P,et al.Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg,Denmark.Stroke,1992,23:1701-1704.
39.Ricci S,Celani MG,La Rosa F,et al.SEPIVAC:a community-based study of stroke incidence in Umbria,Italy.J Neurol Neurosurg Psychiatry,1991,54:695-698.
40.Giroud M,Beuriat P,Vion P,et al.Stroke in a French prospective population study.Neuroepidemiology,1989,8:97-104.
41.Bamford J,Sandercock P,Dennis M,et al.A prospective study of acute cerebrovascular disease in the community:the Oxfordshire Community Stroke Project 1981-86,1:methodology,demography and incident cases of first-ever stroke.J Neurol Neurosurg Psychiatry,1988,51:1373-1380.
42.Bamford J,Sandercock P,Dennis M.Classification and natural history of clinically identifiable subtypes of cerebral infarction.Lancet,1991,337:1521-1526.
43.Foulkes MA,Wolf PA,Price TR,et al.The Stroke Data Bank:design,methods,and baseline characteristics.Stroke,1988,19:547-554.
44.Malmgren R,Warlow C,Bamford J,et al.Geographical and secular trends in stroke incidence.Lancet,1987,2:1196-2000.
45.Bonita R.Epidemiology of stroke.Lancet,1992,339:342-344.
46.Sudlow CLM,Warlow CP.Comparing stroke incidence world-wide:what makes studies comparable?Stroke,1996,27:550-558.
47.Warlow CP.Epidemiology of stroke.Lancet.1998,352(suppl Ⅲ):1-4.
48.Adams HP,Bendixen BH,Kappelle LJ,et al.Classification of subtype of acute ischemic stroke[J].Stroke,1993,24(1):35-41.
49.Albanese MA,Clarke WR,Adams HP,et al.Stroke,1994,25:1746-49.
50.Madden KP,Madden M,Adama HP,et al.Neurology.1995,45:1975-61.
51.Lee LJ,Kidwell CS,Alger J,et al.Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography.Stroke,2000,31:1081-1089.
52.Johnson BA,Haiserman JE.Am J Neuroradiol.1994,15:901-906.
53.Gordon DL,Bendixen BH,Adams HP,et al.Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke[J].Neurology,1993,43(5):1021-27.
54.Goldstein LB,Jones MR,Matchar DB,et al.Improving the reliability of stroke subgroup classification using the trial of 0RG10172 in acute stroke treatment criteria[J].Stroke,2001,32(5):1091-97.
55.Kolom insky-Rabas PL,Weber M,Gefeller O,et al.Epidemiology of ischem-ic stroke subtypes according to TOAST criteria[J].Stroke.2001,32(12):2735-40.
56.Lee BI,Nam HS,Heo JH,et al.Yonsei stroke registry:analysis of 1000 patients with acute cerebral infartion[J].Cerebrovasc Dis,2001,12(3):145-151.
57.Yip PK,Jeng JS,Lee TK,et al.Subtypes of ischem ic stroke:a hospital-based stroke registry in Taiwan(SCAN-IV)[J].Stroke,1997,28(12):2507-2512.
58.Adams H,Davis P.Baseline NIH Stroke Scale score strongly predicts outcome after stroke:A report of t he Trial of Org10172 in Acute Stroke Treatment(TOAST)[J].Neurology,1999,53(1):126-131.
59.Kanda S,Kuzuya M,Ramos MA,et al.Matrix metalloproteinase and α β3 integrin-dependent vascular smooth muscle cee invasion through a type I collagen lattice[J].Arterioscler Thromb Vase Biol.2000,20:998.
60.Liu YN,Pan SL,Peng CY,et al.YC-1[3-(5-Hydroxymethyl-2-furyl)-1-benzyl Indazole]inhibits neointim a formation in balloon-injured rat carotid through suppression of expressions and activities of matrix metallopreteinases 2 and 9[J].J Phamacol Ecp Ther,2006,316:35.
61.Lapchak PA,Chapman DF,Zivin JA.Metallopreteinase inhibition reduces thrombolytic(tissue plasminogen activator) induced hemorrhage after thromboembolic stroke[J].Stroke,2000,31(12):3034-3040.
62.Pfefferkom T,Rosenberg GA.Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion[J].Stroke,2003,34(8):2025-2030.
63.Wilson SH,Herrmann J,Lerman Lo,et al.Aimvastatin preserves the structure of coronary adwentitial vasoram in experimental hypercholesterolemia independent of lipid lowering[J].Circulation,2002,105:415-418.
64.Som JW,Koh KK,Ahm JY,et al.Effects of statin on plague stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease[J].Int J Cardiol,2003,88:77-82.